AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14974733 — intervention group
Group type: COMPARATOR
Intervention: Lactulose - control group
Number of subjects: 9
Study 14974733 — intervention group
Group type: COMPARATOR
Intervention: Sucrose - control group
Number of subjects: 9
Study 14974733 — intervention group
Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII)
Number of subjects: 9
Study 10990166 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine
Number of subjects: 142
Study 10990166 — intervention group
Group type: COMPARATOR
Intervention: IFN-gamma
Number of subjects: 142
Study 9175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated (P-type) RBBs
Number of subjects: 157
Study 9175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched (E-type) RBBs
Number of subjects: 157
Study 9175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebonded RBBs
Number of subjects: 157
Study 1437429 — intervention group
Group type: EXPERIMENTAL
Intervention: High catheters placed in the thoracic aorta (closest to the sixth to eighth thoracic vertebra)
Number of subjects: 970
Study 1437429 — intervention group
Group type: COMPARATOR
Intervention: Low catheters placed in the abdominal aorta (closest to the third to fifth lumbar vertebra)
Number of subjects: 970
Study 1437429 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates weighing 750 to 999 g
Number of subjects: 970
Study 1437429 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates weighing 1000 to 1499 g
Number of subjects: 970
Study 3957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening
Number of subjects: 0
Study 31824507 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV glycoprotein B (gB) vaccine
Number of subjects: 40
Study 28795416 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA 100 mg
Number of subjects: 24
Study 28795416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28795416 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine 5 g
Number of subjects: 24
Study 25772962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packs removed after 12 hours
Number of subjects: 60
Study 25772962 — intervention group
Group type: COMPARATOR
Intervention: Nasal packs removed after 24 hours
Number of subjects: 60
Study 22045782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-based therapy (18 sessions of low-impact therapy)
Number of subjects: 27
Study 21633074 — intervention group
Group type: EXPERIMENTAL
Intervention: HCF diet
Number of subjects: 111
Study 21633074 — intervention group
Group type: EXPERIMENTAL
Intervention: HP diet
Number of subjects: 111
Study 21633074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix diet
Number of subjects: 111
Study 21633074 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 111
Study 19920714 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg twice daily)
Number of subjects: 239
Study 19920714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 16790988 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral electrical stimulation (ES) of the globus pallidus internus
Number of subjects: 18
Study 16790988 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lesion of the globus pallidus internus
Number of subjects: 18
Study 16790988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (lesions and ES)
Number of subjects: 18
Study 15150305 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail FOBT with reminders
Number of subjects: 1451
Study 15150305 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail FOBT without reminders
Number of subjects: 1451
Study 15150305 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 1451
Study 11717600 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned strategy intervention group (n = 80)
Number of subjects: 366
Study 11717600 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 189)
Number of subjects: 366
Study 11717600 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned strategy intervention group (phase 2, n = 366)
Number of subjects: 366
Study 9433585 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative disease classification (Q1)
Number of subjects: 367
Study 9433585 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous disease classification (AF)
Number of subjects: 367
Study 8328559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 35
Study 8328559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3080286 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, 5 doses over 24 hours)
Number of subjects: 30
Study 3080286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 doses over 24 hours)
Number of subjects: 30
Study 30040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 6
Study 30040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 6
Study 30040753 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 6
Study 27875942 — intervention group
Group type: EXPERIMENTAL
Intervention: pico-Tesla Transcranial Magnetic Stimulation (pT-TMS) applied with magnetic field amplitude of 1-7.5 pT and frequency of 8-13 Hz
Number of subjects: 10
Study 25319870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 0
Study 25319870 — intervention group
Group type: COMPARATOR
Intervention: Standard dose vaccine
Number of subjects: 0
Study 21744005 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (AA, 51 g of amino acids and 40 g of carbohydrate)
Number of subjects: 21
Study 21744005 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (PL, 91 g of carbohydrate)
Number of subjects: 21
Study 21744005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail walking in the mountains
Number of subjects: 21
Study 20188470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain+Distraction (video games requiring high attention)
Number of subjects: 0
Study 20188470 — intervention group
Group type: COMPARATOR
Intervention: Pain Alone (capsaicin+heat without distraction)
Number of subjects: 0
Study 20188470 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Alone (video games without pain stimulus)
Number of subjects: 0
Study 17991698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (single oral dose)
Number of subjects: 8
Study 17991698 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (single oral dose)
Number of subjects: 8
Study 17991698 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 8
Study 15647752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 15647752 — intervention group
Group type: COMPARATOR
Intervention: Systematic reviews
Number of subjects: 0
Study 11812698 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Number of subjects: 30
Study 11812698 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 30
Study 10366113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine type II collagen (CII), 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months
Number of subjects: 190
Study 10366113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 7564450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 40
Study 7564450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2289979 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids, red cells, dobutamine, and vasodilators
Number of subjects: 0
Study 2289979 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased DO2 and VO2
Number of subjects: 0
Study 2289979 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7294546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6
Study 31495886 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% fat intervention
Number of subjects: 10
Study 31495886 — intervention group
Group type: COMPARATOR
Intervention: 0% fat intervention
Number of subjects: 10
Study 31495886 — intervention group
Group type: COMPARATOR
Intervention: Fasting intervention
Number of subjects: 10
Study 29239696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade compression garments
Number of subjects: 15
Study 29239696 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-grade compression garments
Number of subjects: 15
Study 29239696 — intervention group
Group type: COMPARATOR
Intervention: Control (loose fitting shorts)
Number of subjects: 15
Study 27917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and asunaprevir
Number of subjects: 26
Study 27917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, daclatasvir, and simeprevir
Number of subjects: 26
Study 27917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, daclatasvir, and asunaprevir
Number of subjects: 26
Study 25085791 — intervention group
Group type: COMPARATOR
Intervention: Expressive suppression (SUPP)
Number of subjects: 36
Study 25085791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance (ACC)
Number of subjects: 36
Study 22094352 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (TRP‐)
Number of subjects: 18
Study 19862609 — intervention group
Group type: COMPARATOR
Intervention: Erythropoiesis stimulating agents (ESA) therapy
Number of subjects: 663
Study 18067807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol preconditioning (2 mg/kg pre-operatively and 5 mg.kg(‐1).h(‐1) intra-operatively)
Number of subjects: 40
Study 18067807 — intervention group
Group type: COMPARATOR
Intervention: Control group (midazolam 0.2 mg/kg pre‐ and 0.1 mg.kg(‐1).h(‐1) intra-operatively)
Number of subjects: 40
Study 18067807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol preconditioning
Number of subjects: 40
Study 18067807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 15187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid solutions as initial volume expanders
Number of subjects: 0
Study 15187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and blood products
Number of subjects: 0
Study 15187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive resuscitations
Number of subjects: 0
Study 15187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel blood substitutes and hypertonic saline
Number of subjects: 0
Study 15187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive hemodynamic monitoring techniques
Number of subjects: 0
Study 11774289 — intervention group
Group type: EXPERIMENTAL
Intervention: L-cysteine-containing tablet
Number of subjects: 9
Study 11774289 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 9
Study 10430253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 77080
Study 10430253 — intervention group
Group type: COMPARATOR
Intervention: No invitation to mammographic screening (Control)
Number of subjects: 77080
Study 8643970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel at 135 mg/m2
Number of subjects: 59
Study 8643970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel combined with cisplatin/etoposide plus radiation therapy
Number of subjects: 59
Study 8643970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel combined with carboplatin and extended-schedule etoposide
Number of subjects: 59
Study 2106783 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA alone
Number of subjects: 64
Study 2106783 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA plus heparin
Number of subjects: 64
Study 2106783 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 64
Study 108738 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana containing 6 mg delta 9‐THC
Number of subjects: 30
Study 108738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30468772 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity Care Intensivist (CCI) intervention
Number of subjects: 0
Study 29557090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2719
Study 29557090 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis (enoxaparin)
Number of subjects: 2719
Study 25433985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fidelity (part task trainer only)
Number of subjects: 69
Study 25433985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fidelity (part task trainer and life sized poster of a pregnant woman)
Number of subjects: 69
Study 25433985 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive fidelity (part task trainer and a simulated standardised patient)
Number of subjects: 69
Study 24118450 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Sandoz)
Number of subjects: 68
Study 24118450 — intervention group
Group type: COMPARATOR
Intervention: Reference tacrolimus
Number of subjects: 68
Study 21196865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoclean
Number of subjects: 90
Study 21196865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 90
Study 21196865 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 90
Study 21196865 — intervention group
Group type: COMPARATOR
Intervention: Infected dentin tubes (positive control)
Number of subjects: 90
Study 21196865 — intervention group
Group type: COMPARATOR
Intervention: Sterile dentin tubes (negative control)
Number of subjects: 90
Study 18957505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 41
Study 18957505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17585011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent P. aeruginosa flagella vaccine
Number of subjects: 483
Study 17585011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 15252415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message intervention during hospitalization and 1 week and 1 month after discharge
Number of subjects: 70
Study 15252415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message intervention
Number of subjects: 70
Study 15317827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) rHuEpo, single doses ranging from 10 to 500 IU/kg
Number of subjects: 0
Study 15317827 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rHuEpo, single doses ranging from 300 to 2400 IU/kg
Number of subjects: 0
Study 15317827 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rHuEpo, multiple doses of 150 IU/kg/3 times a week and 600 IU/kg/week
Number of subjects: 0
Study 15317827 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10510148 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 36
Study 10510148 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 36
Study 10510148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7497561 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg intravenously
Number of subjects: 80
Study 7497561 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 80
Study 7497561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 1742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximine
Number of subjects: 14
Study 1742538 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 14
Study 7092330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) exposure (average 108 micrograms/m3 for 4 hours)
Number of subjects: 35
Study 7092330 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure (control group)
Number of subjects: 35
Study 30609428 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction with music and video games via iPod (n = 109)
Number of subjects: 219
Study 30609428 — intervention group
Group type: COMPARATOR
Intervention: No iPod (control group, n = 110)
Number of subjects: 219
Study 30609428 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction with music and video games via iPod
Number of subjects: 219
Study 28799197 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) intervention
Number of subjects: 0
Study 28799197 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25739527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (n = 134)
Number of subjects: 234
Study 25739527 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 100)
Number of subjects: 234
Study 23715718 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding scientific problems with related heuristic knowledge
Number of subjects: 76
Study 23715718 — intervention group
Group type: COMPARATOR
Intervention: Finding conventional problems without related heuristic knowledge
Number of subjects: 76
Study 21247665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 20
Study 21247665 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly/Bac/Neo
Number of subjects: 20
Study 21247665 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly/Bac
Number of subjects: 20
Study 21247665 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated wound)
Number of subjects: 20
Study 19570236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 19570236 — intervention group
Group type: COMPARATOR
Intervention: Intensified treatment as usual (TAU)
Number of subjects: 0
Study 19570236 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help group intervention (SH)
Number of subjects: 0
Study 17166799 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (higher dose)
Number of subjects: 499
Study 17166799 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (lower dose)
Number of subjects: 499
Study 17166799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 15132726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous GnRH (5 microg every 90 min for 36 hours)
Number of subjects: 19
Study 15132726 — intervention group
Group type: COMPARATOR
Intervention: Single dose GnRH-agonist stimulation test (buserelin acetate, 10 microg/kg body weight)
Number of subjects: 19
Study 11478009 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 64
Study 11478009 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study 9736567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day PMPA
Number of subjects: 20
Study 9736567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day PMPA
Number of subjects: 20
Study 9736567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8070432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 75
Study 8070432 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 75
Study 31976596 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA interference targeting HPV16 E6/E7 gene
Number of subjects: 226
Study 31976596 — intervention group
Group type: EXPERIMENTAL
Intervention: p16INK4a gene
Number of subjects: 226
Study 31976596 — intervention group
Group type: EXPERIMENTAL
Intervention: hTERC gene
Number of subjects: 226
Study 31976596 — intervention group
Group type: COMPARATOR
Intervention: p16INK4a, Notch1, and hTERC genes
Number of subjects: 226
Study 29998809 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tube intubation and tube stenting (Group 1)
Number of subjects: 70
Study 29998809 — intervention group
Group type: COMPARATOR
Intervention: Silicone tube intubation only (Group 2)
Number of subjects: 70
Study 27740930 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 177
Study 27740930 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 177
Study 27740930 — intervention group
Group type: COMPARATOR
Intervention: NGT-hyperinsulinemia (NGT-HI)
Number of subjects: 177
Study 27740930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall glucose metabolism alterations
Number of subjects: 177
Study 27740930 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR levels
Number of subjects: 177
Study 25168278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge)
Number of subjects: 0
Study 25168278 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 0
Study 23558602 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound omeprazole capsule (40 mg)
Number of subjects: 42
Study 23558602 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release omeprazole (40 mg)
Number of subjects: 42
Study 20513826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Medical Clinics (GMC)
Number of subjects: 239
Study 20513826 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 239
Study 18715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + electrolyte solution
Number of subjects: 16
Study 18715125 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 16
Study 16790114 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative ovarian surgery (Group I)
Number of subjects: 99
Study 16790114 — intervention group
Group type: COMPARATOR
Intervention: ICSI cycle directly (Group II)
Number of subjects: 99
Study 14644891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy for at least 3 months
Number of subjects: 4374
Study 14644891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy for more than 3 months
Number of subjects: 4374